OCEA vs. IMAB, RGLS, SKYE, KPTI, CUE, GNLX, EPRX, VTGN, APLT, and ALTS
Should you be buying Ocean Biomedical stock or one of its competitors? The main competitors of Ocean Biomedical include I-Mab (IMAB), Regulus Therapeutics (RGLS), Skye Bioscience (SKYE), Karyopharm Therapeutics (KPTI), Cue Biopharma (CUE), Genelux (GNLX), Eupraxia Pharmaceuticals (EPRX), Vistagen Therapeutics (VTGN), Applied Therapeutics (APLT), and Janone (ALTS). These companies are all part of the "pharmaceutical preparations" industry.
Ocean Biomedical vs.
Ocean Biomedical (NASDAQ:OCEA) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
Ocean Biomedical has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
I-Mab has a consensus target price of $8.00, indicating a potential upside of 633.94%. Given I-Mab's stronger consensus rating and higher probable upside, analysts plainly believe I-Mab is more favorable than Ocean Biomedical.
In the previous week, I-Mab had 1 more articles in the media than Ocean Biomedical. MarketBeat recorded 1 mentions for I-Mab and 0 mentions for Ocean Biomedical. I-Mab's average media sentiment score of 1.93 beat Ocean Biomedical's score of 0.00 indicating that I-Mab is being referred to more favorably in the news media.
Ocean Biomedical has higher earnings, but lower revenue than I-Mab.
I-Mab received 55 more outperform votes than Ocean Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ocean Biomedical an outperform vote while only 64.13% of users gave I-Mab an outperform vote.
24.6% of Ocean Biomedical shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 73.5% of Ocean Biomedical shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
I-Mab beats Ocean Biomedical on 9 of the 13 factors compared between the two stocks.
Get Ocean Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocean Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:OCEA) was last updated on 1/22/2025 by MarketBeat.com Staff
